Actinium Pharmaceuticals, Inc.

The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases Phase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy Memorial Sloan Kettering Cancer Center study demonstrates promise of Iomab-ACT as targeted conditioning agent before CAR T-cell therapy, with a focus on CAR T-cell expansion, imm…

Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage chemotherapy Findings support development of Actimab-A as a potential mutation-agnostic AML backbone, building on prior clinical activity following venetoclax failure and in TP53-mutated disease NEW YORK, Nov. 4, 2026 …

Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes ATNM-400 is a first-in-class targeted alpha therapy directed against HER3, a driver of tumor biology and treatment resistance in multiple solid tumors Breast cancer findings reinforce ATNM-400's pan-tumor potential, building on previously reported preclinical results in non-small cell lung, colorectal and ovarian cancers  NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Actinium Pharmaceutical…

NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive employee. On October 26, 2026, the Company granted the employee a non-qualified stock option to purchase 3,000 shares of the Company's common stock at an exercise price of $1.40 per share, equal to the closing price of Actinium's common stock on…

First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha radiotherapy offers a differentiated approach through a target distinct from PSMA and the potential to address treatment resistance across multiple solid tumors NEW YORK, Oct. 23, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer …

Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) and Cytokinetics (NASDAQ: CYTK - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership. Earnings and Valuation This table compares Actinium Pharmaceuticals and

HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day half‑life Initial three‑patient cohort completed the first dose level of 1.0 µCi/kg with no dose‑limiting toxicities, xerostomia or Grade 3/4 hematologic adverse events observed ATNM‑400 advanced to the second dose level of 1.5 µCi/kg, marking continued clinical progress for a first‑in‑class Actini…

ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatments In colorectal cancer, adding ATNM-400 to standard therapy increased tumor growth inhibition to 72% from 25% for oxaliplatin and bevacizumab in a poorly responsive model with moderate target expression In ovarian cancer, ATNM-400 achieved 93% tumor growth inhibition as monotherapy and retained activity followin…

First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to feature ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer, exploring its potential across molecular subtypes ATNM-400's HER3-targeted alpha radiotherapy approach offers pan-cancer potential, with development as a monotherapy and in combination with established treatments across multi…

NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced inducement equity awards to Matt David, M.D., the Company's newly appointed Chief Financial Officer, and Sean Maenpaa, the Company's newly appointed Senior Vice President, Business Development.

Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal cancer data demonstrate ATNM-400's potential to enhance responses to standard-of-care therapies Ovarian cancer data demonstrate the durable antitumor activity of ATNM-400, including in treatment-resistant models Collectively, the findings support the broad potential of ATNM-400 as a differentiated tar…

– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals and BWXT Medical – Will lead partnering, licensing and strategic transactions across Actinium's targeted radiotherapy pipeline NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiothera…

Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation of Zirconium-89-labeled ATNM-400 to assess safety, biodistribution, and dosimetry to inform the development of Actinium-225-labeled ATNM-400 as a targeted radiotherapy ATNM-400 is a first-in-class, non-PSMA targeted radiotherapy being developed to address a broad mCRPC patient population, including P…

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.

Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) and Actinium Pharmaceuticals (NYSE: ATNM - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, profitability and dividends. Analyst Recommendations This is a summary of

NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sandesh Seth, Chairman and Chief Executive Officer, will present at the H.C.

NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including recently acquired patents adding to a broad suite of IP, and expansion of the Company's manufacturing capacity, as the program approaches clinical milestones from the fourth quarter of 2026 and into 2027. The Company also provided an update on the status of …